Table 1

Characteristics of included meta-analyses

CharacteristicsAll (n=291)Significant (n=118)Non-significant (n=173)
The number of RCTs included in each meta-analysis, M (P25, P75)4.00 (3.00, 8.00)5.00 (3.00, 9.00)4.00 (3.00, 7.00)
Sample size, M (P25, P75)805.00 (462.00, 1569.50)974.00 (482.00, 2447.25)726.00 (438.00, 1330.00)
Total number of events, M (P25, P75)142.00 (49.00, 350.50)212.00 (62.00, 447.75)107.00 (41.00, 291.00)
I2, %, M (P25, P75)4.00 (0.00, 45.45)11.00 (0.00, 44.00)0.00 (0.00, 50.00)
FI, M (P25, P75)7.00 (4.00, 15.00)8.00 (3.00, 24.00)7.00 (4.00, 12.00)
Effect size, M (P25, P75)1.00 (0.54, 1.21)1.00 (0.36, 1.67)1.00 (0.69, 1.11)
Width of CI, M (P25, P75)1.00 (0.41, 1.68)1.00 (0.26, 1.58)1.00 (0.53, 1.71)
Study field, n (%)
 Venous81 (27.84)27 (22.88)54 (31.21)
 Aortic41 (14.09)17 (14.41)24 (13.87)
 Peripheral arterial96 (32.99)48 (40.68)48 (27.75)
 Vascular access62 (21.31)20 (16.95)42 (24.28)
 Others11 (3.78)6 (5.08)5 (2.89)
Outcome type, n (%)
 Non-mortality226 (77.66)104 (88.14)122 (70.52)
 Mortality65 (22.34)14 (11.86)51 (29.48)
Effect measure, n (%)
 OR147 (50.52)69 (58.47)78 (45.09)
 RD4 (1.37)1 (0.85)3 (1.73)
 RR140 (48.11)48 (40.68)92 (53.18)
Method used, n (%)
 DL14 (4.81)4 (3.39)10 (5.78)
 IV44 (15.12)21 (17.80)23 (13.29)
 MH233 (80.07)93 (78.81)140 (80.92)
Model used, n (%)
 Fix-effect model128 (43.99)61 (51.69)67 (38.73)
 Random-effect model163 (56.01)57 (48.31)106 (61.27)
Fundings, n (%)
 No233 (76.63)94 (79.66)129 (74.57)
 Yes68 (23.37)24 (20.34)44 (25.43)
  • DL, DerSimonian and Laird; FI, Fragility Index; IV, inverse variance; M, median; MH, Mantel-Haenszel; P25, 25th percentile; P75, 75th percentile; RCTs, randomised controlled trials; RD, risk difference; RR, risk ratio.